Although RA is associated with significant morbidity, the increasing number of effective drugs and modes of action has improved the disease outcome. Currently, several US Food and Drug Administration ...

IL-17 is a proinflammatory cytokine mediating protumorigenic and proangiogenic effects. Monoclonal antibodies targeting IL-17/IL-17-receptor or impairing expansion of IL-17-producing cells may ...

Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may ...

Dr. Yeilding received options to purchase 38,520 shares and restricted stock units (RSUs) to acquire 31,779 shares of Protagonist Therapeutics common stock. The exercise price of the options is $38.98 ...

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to the class leader.

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR ) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR ), today announced significant progress in ...

Extensive data support a key role for toll-like receptors (TLRs) in RA. Little is known regarding the impact of hypoxia ... leading to proinflammatory IFN-γ and IL-17 production. Conclusions Our ...

The following is a summary of “FC02 Immune cell signatures and T-cell receptor profiling reveal pathogenetic mechanisms in psoriasis,” published in the December 2024 issue of Dermatology by Deng et al ...

Receptor pharmacology is the study of the interactions of receptors with drugs/pharmaceuticals and other xenobiotics. A basic tenet of receptor pharmacology is that a drug’s effect is directly ...

Cell therapies have suffered from hyped-up expectations, clinical setbacks and high costs. But maybe, just maybe, Arovella is ...

The three-signal model provides an empirical framework for innate instruction of adaptive immunity, but mainly discusses STAT-dependent cytokines in T cell activation and differentiation, while the ...

This study addresses fundamental questions surrounding otitis media effusion in Down syndrome, identifying DYRK1A as a key gene involved in the condition. The findings are compelling, highlighting ...